Business Context and Reporting Period
This Form 8-K, dated June 22, 2026, reports a significant executive leadership change at QuidelOrtho Corporation. The filing announces the appointment of a new Chief Financial Officer (CFO) and details the transition plan for the outgoing CFO.
Key Financial Metrics
This filing does not contain operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data presented relates exclusively to executive compensation and severance arrangements.
- New CFO Base Salary: $750,000 annually.
- New CFO Target Cash Bonus: 100% of base salary.
- New CFO Sign-on Cash Bonus: $500,000.
- New CFO Inducement Equity Grant: $6,500,000 in Restricted Stock Units (RSUs), vesting over three years.
- Outgoing CFO Transition Salary: $340,000 annual rate for six months post-transition.
- Outgoing Advisor Salary: $100,000 annual rate for up to 24 months.
Material Changes
The primary material change is the departure of Joseph M. Busky as CFO and the appointment of Micah Young, effective July 6, 2026. Mr. Busky, who previously announced his retirement, will transition to a special advisor role. Mr. Young joins from Masimo Corporation, where he served as CFO until its acquisition by Danaher Corporation in June 2026.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of market risks. It focuses on the terms of employment, including severance and change-in-control protections for the new CFO. Under the Severance and Change in Control Agreement, Mr. Young is entitled to severance benefits (including two times the sum of base salary and bonus) in the event of a qualifying termination without cause, and full acceleration of equity awards in the event of a change in control.
Investor Verification Checklist
- Verify the effective date of the CFO transition (July 6, 2026) and the duration of the outgoing CFO's advisory role.
- Review the total value of the inducement package ($7.05 million in cash and equity) relative to the company's current compensation structure.
- Confirm the vesting schedule for the $6.5 million RSU grant (equal annual installments over three years).
- Assess the impact of the new CFO's background in medical technology (Masimo, NuVasive, Zimmer) on the company's strategic direction.
- Check the specific terms of the Severance and Change in Control Agreement referenced in the filing for potential future liabilities.